• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

By: Lowey Dannenberg, P.C. via GlobeNewswire
June 23, 2025 at 10:34 AM EDT

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) for violations of the federal securities laws on behalf of investors who purchased or acquired UroGen securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).

On May 29, 2025, a complaint was filed against the Company and certain of its current and former officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA’s warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

When investors learned the truth, UroGen’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $50,000 in UroGen’s securities, and wish to participate, or learn more, click here, please contact our attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com).

Any investor who wishes to serve as Lead Plaintiff must act before July 28, 2025.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: afarah@lowey.com

SOURCE: Lowey Dannenberg P.C.


Primary Logo

More News

View More
Tractor Supply Revs Up on Forecast Hike and Bullish Signals
Today 12:10 EDT
Via MarketBeat
Tickers TSCO
3 Short Squeeze Candidates With Big Catalysts on the Horizon
Today 11:03 EDT
Via MarketBeat
Tickers AMC NVDA NVTS OPEN
CrowdStrike Scores Big With Gartner, But Valuation Is Stretched
Today 10:27 EDT
Via MarketBeat
Topics Artificial Intelligence Malware
Tickers CRWD PANW
Intel's Turnaround Gains Credibility With Strong Q2 Report
Today 10:25 EDT
Via MarketBeat
Tickers INTC NVDA
Quantum Gold Rush: The Catalysts Driving Quantum Stocks Higher
Today 10:13 EDT
Via MarketBeat
Tickers QBTS QUBT RGTI
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap